ANNOUNCEMENT

MedCity CONVERGE July 9-10 in Philly gathers payers, providers, medtech, pharma, digital health, policymakers & more.

Topic: PFE

Pfizer settles Celebrex lawsuit; agrees to pay $164 million

Pfizer settles Celebrex lawsuit; agrees to pay $164 million

October 9, 2012 5:42 pm by | 0 Comments

(Reuters) - Pfizer Inc has agreed to pay $164 million to settle a shareholder class action accusing the drug maker of misrepresenting the clinical trial results for Celebrex.The settlement was ... Read more
Pfizer’s Torisel didn’t help renal cell cancer when combined with Avastin

Pfizer’s Torisel didn’t help renal cell cancer when combined with Avastin

August 10, 2012 8:22 am by | 0 Comments

Pfizer Inc said on Friday that a late-stage trial of its drug for renal cell cancer failed to meet its main goal when given in combination with Avastin, a drug ... Read more
Will Pfizer, J&J’s failed Alzheimer’s drug someday be a pre-Alzheimer’s drug?

Will Pfizer, J&J’s failed Alzheimer’s drug someday be a pre-Alzheimer’s drug?

August 7, 2012 6:41 pm by | 0 Comments

Pfizer and Johnson & Johnson's Alzheimer's drug failed to help patients showing early signs of the disease, but it could get another chance as scientists test whether the devastating illness ... Read more
Pfizer pays $60.2 million to end foreign bribery investigation

Pfizer pays $60.2 million to end foreign bribery investigation

August 7, 2012 11:58 am by | 0 Comments

(Reuters) - Pfizer Inc has agreed to pay $60.2 million to settle a U.S. government probe of the drugmaker's alleged use of illegal payments to win business overseas, according to ... Read more
Pfizer bids farewell to Alzheimer’s disease drug bapineuzumab

Pfizer bids farewell to Alzheimer’s disease drug bapineuzumab

August 6, 2012 5:21 pm by | 0 Comments

A closely watch Alzheimer's drug being developed by Pfizer Inc and Johnson & Johnson failed to meet the main goals of a late stage clinical trial, and the companies said ... Read more
Pfizer coping well with loss of Lipitor patent, so what’s the outlook for blockbuster replacements?

Pfizer coping well with loss of Lipitor patent, so what’s the outlook for blockbuster replacements?

August 1, 2012 11:02 am by | 0 Comments

Pfizer’s (NYSE:PFE) 25 percent profit growth with $15 billion in revenue came as a surprise to some expecting the company to still be hurting from the loss of its patent ... Read more
FDA green lights Pfizer’s blockbuster drug Lyrica for spinal injury patients

FDA green lights Pfizer’s blockbuster drug Lyrica for spinal injury patients

June 21, 2012 9:06 am by | 0 Comments

The U.S. Food and Drug Administration has approved the expanded use of Pfizer’s (NYSE:PFE) blockbuster pain medication Lyrica for neuropathic pain associated with spinal injury, according to a company statement.It ... Read more
PPD names Pfizer executive David Simmons its new CEO

PPD names Pfizer executive David Simmons its new CEO

May 23, 2012 11:46 am by | 0 Comments

Clinical research organization PPD has hired a Pfizer (NYSE:PFE) veteran to become its new CEO.David Simmons brings 15 years experience at the world’s largest pharmaceutical company to PPD, which is ... Read more
Antares inks licensing agreement with Pfizer

Antares inks licensing agreement with Pfizer

December 20, 2011 5:05 pm by | 0 Comments

Antares Pharma (AMEX:AIS) has inked a licensing agreement with Pfizer (NYSE:PFE) to provide one of its drug-delivery technologies to Pfizer’s consumer healthcare business arm for an unnamed product for North ... Read more
PFE gives ICGN shareholders last chance to accept $56M deal

PFE gives ICGN shareholders last chance to accept $56M deal

September 13, 2011 10:44 am by | 0 Comments

Nearly one-third of Icagen (NASDAQ:ICGN) shareholders have yet to accept Pfizer‘s (NYSE:PFE) $56 million offer for the pain drug development company and the pharmaceutical giant is giving them one last ... Read more
Pfizer secures enough shares for Icagen acquisition

Pfizer secures enough shares for Icagen acquisition

September 6, 2011 11:04 am by | 0 Comments

Pfizer‘s (NYSE:PFE) Icagen (NASDAQ:ICGN) acquisition is a go.After two extensions last week, Pfizer announced today that it has enough shares tendered for sale for the $56 million cash deal to ... Read more
Pfizer’s Icagen offer extended again; now expires at 6 p.m.

Pfizer’s Icagen offer extended again; now expires at 6 p.m.

September 2, 2011 9:57 am by | 0 Comments

Icagen‘s (NASDAQ:ICGN) sale to Pfizer (NYSE:PFE) hangs in the balance by 39,799 shares.That’s the minimum number of shares that need to be tendered for the $56 million sale to proceed. ... Read more
Pfizer extends Icagen offer; remains just shy of shares needed for deal

Pfizer extends Icagen offer; remains just shy of shares needed for deal

September 1, 2011 10:26 am by | 0 Comments

Pfizer‘s (NYSE:PFE) $56 million offer for Icagen (NASDAQ:ICGN) has been extended one more day as the pharmaceutical giant remains just shy of the minimum shares needed to execute the acquisition.Unless ... Read more
PFE to ICGN shareholders: ‘$6 per share is our best and final price’

PFE to ICGN shareholders: ‘$6 per share is our best and final price’

August 26, 2011 4:56 pm by | 0 Comments

Pfizer (NYSE:PFE) will not raise its offer to acquire Icagen (NASDAQ:ICGN).The pharmaceutical giant sent a letter to Icagen’s board of directors today holding firm on its purchase price of $6 ... Read more
Pharmas will monitor Facebook posts after site changes pharmas’ wall policy

Pharmas will monitor Facebook posts after site changes pharmas’ wall policy

August 15, 2011 4:20 pm by | 0 Comments

Pharmaceutical companies on Facebook for years have had a decidedly one-way relationship on the social networking site: Pharmas could post about their drugs, but the public could not write on ... Read more